Rodman & Renshaw Capital Group Inc. 

(Public, NASDAQ:RODM)   Watch this stock   
Find more results for RODM
Oct 22, 2009
Q3 2009 RODMAN & RENSHAW CAP GP INC Earnings Conference Call - Webcast
Oct 22, 2009
Q3 2009 RODMAN & RENSHAW CAP GP INC Earnings Release
Sep 9, 2009
RODMAN & RENSHAW CAP GP INC at Rodman & Renshaw Annual Global Investment Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 46.59% -76.11%
Operating margin 46.65% -71.06%
EBITD margin - -66.22%
Return on average assets 143.53% -62.63%
Return on average equity 132.50% -82.01%
Employees 130 -

Address

1251 Avenue of the Americas 20th Floor
New York, NY 10020
United States - Map
+1-212-3560500 (Phone)
+1-212-5815690 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

Rodman & Renshaw Capital Group Inc. discussed on blogs

Rodman & Renshaw Capital Group Inc. discussions

  View all discussions »

Description

Rodman & Renshaw Capital Group, Inc. (RRCG) is a holding company that through its various subsidiaries is engaged in the investment banking business. RRCG’s principal operating subsidiary is Rodman & Renshaw, LLC (R&R). R&R is a broker dealer registered with the Financial Industry Regulatory Authority, Inc. (FINRA). The Company is a full service investment bank providing corporate finance, strategic advisory and related services to companies. It also provides research, and sales and trading services to institutional investors. RRCG’s business consists of investment banking, which includes corporate finance and strategic advisory services; sales and trading; equity research, and principal transactions. In October 2009, Rodman & Renshaw Capital Group Inc. announced that its affiliate, Aceras BioMedical LLC, has sold Huxley Pharmaceuticals Inc. to BioMarin Pharmaceutical, Inc.

Officers and directors

Wesley K. Clark
Chairman of the Board
Age: 64
Bio & Compensation - Reuters
Edward Rubin
President, Chief Executive Officer, Director
Age: 41
Bio & Compensation - Reuters
Michael Vasinkevich
Vice Chairman of the Board
Age: 41
Bio & Compensation - Reuters
David Jay Horin
Chief Financial Officer
Age: 40
Bio & Compensation - Reuters
John J. Borer III
Senior Managing Director, Head of Investment Banking, Director
Age: 51
Bio & Compensation - Reuters
Sam Dryden
Director
Age: 59
Bio & Compensation - Reuters
Richard M. Cohen
Director
Age: 58
Bio & Compensation - Reuters
Mark L. Friedman
Director
Age: 61
Bio & Compensation - Reuters
Winston J. Churchill
Director
Age: 68
Bio & Compensation - Reuters
Peter F. Drake Ph.D.
Director
Age: 55
Bio & Compensation - Reuters